COBRE Center for Cancer Research Development

蛋白质组学核心 项目摘要/摘要 罗德岛医院的Cobre CCRD蛋白质组学核心B(Cobre PC)提供了 研究人员使用最新的质谱学仪器进行蛋白质组学研究，从而 保持其对罗德岛州的独特性。在第二阶段，仪器升级导致 Q Exactive Orbitrap LC-MS/MS系统的放置以及UltraFlExtreme MALDI TOF/TOF成像 质谱仪(Bruker Daltonics)使我们的研究人员受益于最先进的技术 仪器仪表。核心，在第三阶段，将努力继续其杰出的服务记录。详细 已经为核心制定了业务计划，并从该机构获得了财务支持 保证使核心在第三阶段期间和之后蓬勃发展。提出了以下具体目标： 1.为研究人员提供最先进的蛋白质纯化和分析仪器 罗德岛和东北地区的学术、临床和生物技术部门。 2.提供个人咨询，描述服务，参与实验设计，解释预期 调查结果，解释数据，并为外部资金努力做出贡献，特别关注初级调查人员 已获得CCRD的试点补助金核心D的支持。 3.提供多样化和独特的蛋白质组学服务，以及分析/生物信息学工具 一名指定的生物信息学家。 4.推动罗德岛医院和更广泛的学术界的翻译研究 与CCRD的分子病理学核心C保持密切的工作关系，并鼓励 使用核心肿瘤库中的癌症组织。

Proteomics Core Project Summary/Abstract The COBRE CCRD Proteomics Core B (COBRE PC) at the Rhode Island Hospital provides the ability for investigators to perform proteomics studies using the latest instrumentation in mass spectrometry and thereby maintains its uniqueness to the state of Rhode Island. During Phase II, instrument upgrades led to the placement of a Q Exactive Orbitrap LC-MS/MS system as well as a UltraFlextreme MALDI TOF/TOF Imaging Mass Spectrometer (Bruker Daltonics) allowing our investigators to benefit from state-of-the-art instrumentation. The Core, during Phase III, will strive to continue its outstanding record of service. Detailed business plans have been formulated for the Core and financial support from the institution has been guaranteed to allow the Core to thrive during and after Phase III. The following specific aims are proposed: 1. To make instrumentation available for state of the art protein purification and analysis to researchers in the academic, clinical and biotechnology sectors in Rhode Island and the Northeast region. 2. To provide personal consultation to describe services, participate in experimental design, explain expected findings, interpret data and contribute to extramural funding efforts with a special focus on junior investigators who have obtained support from the CCRD's Pilot Grants Core D. 3. To provide diverse and unique service in proteomics along with analytic/bioinformatic tools with the addition of a designated bioinformatician. 4. To advance translational research at the Rhode Island Hospital as well as the greater academic community by maintaining a close working relationship with the CCRD's Molecular Pathology Core C and encourage the use of cancerous tissue from the Core's Tumor Bank.